Oxnard-based Cure Pharmaceutical, a drug delivery platform and CBD products company, reported more losses but rising revenue in its second quarter earnings. Cure suffered a net loss of $9.6 million in the second quarter of 2022, up substantially from a net loss of $1.3 million in the same quarter a year ago. That equates to Read More →
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Camarillo-based Semtech produced record revenue and earnings in the second quarter of 2022, but its shares plummeted 27% the day after its earnings release after the company’s guidances for the third quarter were well below analysts’ expectations. Semtech, a semiconductor company specializing in Internet of Things applications, saw its net income increase in the second Read More →
Amgen announced positive results from clinical trials of two separate drugs in late August. On Aug. 30, the Thousand Oaks-based biotech giant said its Phase 3 trail evaluating daily oral doses of Lumakras, a treatment for non-small cell lung cancer, “met its primary endpoint of progression-free survival” and demonstrated statistically significant superiority over the current Read More →
Westlake Village-based Dole beat analysts’ expectations when it reported positive earnings per share for the second quarter on Aug. 23, but the company also slashed its guidance for revenue and earnings for the full year. Dole, one of the largest fruit and vegetable producers in the world, is dually headquartered in Westlake Village and Dublin, Read More →
Goleta-based Transphorm just missed analysts’ expectations when it reported its first quarter earnings on Aug. 15. Transphorm, a supplier of gallium nitride power conversion products, reported an adjusted earnings per share loss of 8 cents for the quarter ended June 30, one cent higher than Zacks Consensus Estimate. The company also reported a loss of Read More →